logo
Plus   Neg
Share
Email

UK CMA Probes Apple Over Suspected Anti-competitive Behavior - Quick Facts

The United Kingdom's Competition and Markets Authority (CMA) has launched an investigation into technology giant Apple Inc. (AAPL) following complaints that its terms and conditions for app developers are unfair and anti-competitive.

iPhone maker Apple also operates the App Store, which is the only way for developers to distribute third-party apps on Apple's iPhones and iPads, and the only way for Apple customers to access them.

The probe has been prompted by the CMA's own work in the digital sector, as well as several developers reporting that Apple's terms and conditions are unfair and could break competition law.

Apple requires that all apps available through the App Store have to be approved by it. This approval hinges on developers agreeing to certain terms. Only Apple can distribute their apps to iPhones and iPads via the App Store.

Apple charges a commission of up to 30 percent to developers on the value of payment transactions or any time a consumer buys their app.

The CMA's investigation will consider whether Apple has a dominant position in connection with the distribution of apps on Apple devices in the UK and whether Apple imposes unfair or anti-competitive terms on developers.

The European Commission (EC) currently has four open antitrust probes into Apple.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
Follow RTT